EMIG Logo

Welcome to EMIG

We are a multi-stakeholder network and trade association that represents the interests of life sciences companies in the UK

For Members

EMIG members' medical industry knowledge must be current in a landscape that is constantly changing. Through the EMIG platform, our online and in-person events, members can network and exchange information.

What is the EMIG platform?

Our exclusive platform enhances your membership with a personalised dashboard that provides easy access to:

  • Network

    Network

    Submit questions or requests anonymously to the Network and receive curated responses, or search the directory for previously asked questions

  • Events

    Events

    View and register for upcoming events by interest group, track your personal event schedule, and join live sessions directly through the platform

  • Resources

    Resources

    Quick access to documents, videos, and podcasts

Featured Network Questions

Tap into the collective expertise of the EMIG network. Browse recent questions and curated responses, or submit your own inquiries to connect with industry peers.

  • We are looking for an experienced Regulatory Affairs professional (Head of Regulatory, Regulatory Director, or equivalent) to coach and mentor our Regulatory Affairs lead

  • Can anyone recommend a reliable temperature monitoring system/supplier for a pharmaceutical warehouse operating under GDP requirements?

  • We're a small UK company looking for flexible, small marketing agencies to collaborate with for 2027.

  • I am looking for a Supply Chain expert with knowledge and connections in the Nordic (Sweden/Denmark priority) markets who could support on a project basis.

Featured Events

Below are upcoming events that may be relevant to EMIG members, register your attendance now.

  • EMIG Patient Organisation meeting - Presentation of findings and final recommendations

    London
    Hosted by: EMIG

    Agenda: Presentation of findings and final recommendations

  • Women in Pharma Meeting

    London
    Hosted by: EMIG

    Agenda: Patti Seabright will be speaking on improving yourself for career progression. Meeting sponsored by Macdonald Lewis Associates and Alchemist Consulting

  • EMIG Parliamentary Dinner

    London
    Hosted by: EMIG

    Agenda: Our guest speaker is Baronnes Ayesha Hazarika MBE, a Scottish politician, political commentator and former political adviser to senior Labour Party politicians, who we have enjoyed as a previous speaker. Tickets include a drinks reception, followed by a 3 course dinner with wine and cost £350 each or a table of 10 is £2750. Bring colleagues to enjoy this informal networking event.

  • EMIG Compliance online meeting

    Zoom WebinarZoom Webinar
    Hosted by: External

    Agenda: EMIG Meeting: Pharma and Competition Law: The Big Picture in 2026 The talk will cover: 1. An overview of competition law as it applies to the pharmaceuticals sector. 2. Developments in the law of excessive pricing. 3. The emergence of damages claims by the NHS against pharmaceutical companies. 4. The import of US-style class actions to this jurisdiction.

Featured Resources

Our resources library offers easy access to useful materials including presentations, documents, videos and podcasts. The resources are organised by most recent date upload but you can sort, filter and search by the name of the event, category or file type.

  • Link

    Supply Chain

    Ensuring the efficient supply of medicines to patients

  • Document

    Commercial

    UK FRN Single National Pharmacy Report

  • Document

    Commercial

    UKFRN Future Pharmacy Report

  • Document

    Commercial

    UKFRN 10 Year Plan report

Special Interest Groups

Special Interest Groups

We have 14 SIGs which reflect the myriad demands on the professionals that are vital to a successful biopharmaceutical company. SIGs meet quarterly and inform EMIG members' views on a wide range of issues, from regulation and research to pricing and orphan diseases.

Each group has a chair, and determines the content of each meeting agenda.

EMIG is represented on the following:

  • DHSC

    The Department of Health & Social Care in London is a ministerial department responsible, inter alia, for England's NHS, the health of the nation and access to medicines. EMIG works closely with the Department on issues such as medicines supply and pricing.

  • MHRA

    The Medicines and Healthcare Regulatory Authority is responsible to the DHSC for ensuring that medicines and medical devices in the UK work and are acceptably safe. EMIG works closely with the MHRA, HTA agencies and the NHS to ensure the prompt availability of new medicines to patients.

  • AWTTC

    The All Wales Therapeutics and Toxicology Centre advise on new medicines to ensure they are used effectively and appropriately in Wales and EMIG has a seat on the AWTTC Committee.

  • EUCOPE

    The European Confederation of Pharmaceutical Entrepreneurs has been the voice of small and mid-sized pharmaceutical and biotech companies in Europe for the last 15 years. EMIG has been part of EUCOPE from the outset and Leslie Galloway is Vice president of the Board.

Our Priorities

A healthy life sciences sector

Our Priorities
  • 1
    Driving the opportunities that the VPAG agreement offers the NHS
  • 2
    Supporting a vibrant research community
  • 3
    Expanding a large and highly skilled manufacturing sector
  • 4
    A concentration of leadership and commercial expertise
  • 5
    Ensuring a flexible and supportive licensing and reimbursement process
  • 6
    A sophisticated and world-beating life sciences support services sector
  • 7
    A connected regulatory, HTA and reimbursement process to accelerate patient access

Support the rebuild of the UK and NHS

  • Illustrate the benefits of the VPAG Agreement £400m Industry Investment Facility to stakeholders
  • Persuade global decision makers to invest in the UK
  • Ensure innovative medicines reach UK patients
  • Demonstrate how the implementation of the VPAG can support NHS affordability
  • Enable

    Enable

    ...a vibrant research and development community through advocating for the creation of a life sciences sector research collaborative.

  • Encourage

    Encourage

    ...the building of a large and highly skilled manufacturing sector by pressing for capital investment allowances and tax credits at competitive levels.

  • Develop

    Develop

    ...a concentration of commercial expertise and encourage global pharmaceutical HQs to locate their commercial centres in the UK.

  • Accelerate

    Accelerate

    ...patient access to innovative medicines by developing marketing authorisation and health technology assessment in parallel, where companies opt to do so.

  • Leverage

    Leverage

    ...the life science sector's support services of the future through the UK's reputation for world-leading HTA assessment.